Skip to content

Study · Animal study (in vivo) · mouse · 1990

1 result

Reovirus type 2-induced diabetes in mice prevented by immunosuppression and thymic hormone.

Onodera T, Taniguchi T, Yoshihara K, Shimizu S, Sato M, Hayashi T

Diabetologia1 Apr 1990Cited by 18 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In reovirus-infected mice, serum thymic factor reduced or prevented development of the diabetes-like syndrome.

    In plain wordsIn reovirus-infected mice, serum thymic factor reduced or prevented a diabetes-like syndrome.

    Outcome
    DecreaseDevelopment of diabetes-like syndrome
    Study

    mousen: not reported in source

    Reovirus type 2-infected NC mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The administration of either anti-thymocyte serum or serum thymic factor reduced or prevented the development of the diabetes-like syndrome, while Arg-Lys-Asp-Val-Try did not show any therapeutic effects.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.